Company intelligence / Profile preview

CorDx

Ownership: Private
Employees: ~2100
Development stage: Commercial

Overview

CorDx develops and markets rapid testing and point-of-care diagnostic solutions for infectious diseases such as COVID‑19 and influenza, as well as pregnancy tests and drug screening. The company operates globally with a strong supply chain presence in over 100 countries. Its products are used by healthcare providers to deliver timely results for critical health conditions. The company leverages advanced technology including AI/data science to enhance its offerings.

Therapeutic areas: PsychiatryWomen's HealthInfectious Diseases
Modalities: Diagnostic devices (rapid tests)Point-of-care diagnostics
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on CorDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CorDx.

Explore the full profile